SCHEMBL7704965

SCHEMBL7704965

CC1=C(N)Nc2cc(CN(Cc3ccc(Cl)cc3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
NCOR2 Q9Y618 1/20 0.36
NR1D1 P20393 1/20 0.34
NR1H3 Q13133 1/20 0.34
MAPT P10636 4/20 0.33
TP53 P04637 2/20 0.33
THRB P10828 2/20 0.33
MEN1 O00255 5/20 0.32
KMT2A Q03164 5/20 0.32
MT-CO2 P00403 1/20 0.32
POLB P06746 3/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
GAA P10253 2/20 0.31
CYP3A4 P08684 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711366 0.92 HDAC1 (0.37) HDAC3HDAC1HDAC2NCOR2ALDH1A1
SCHEMBL7708189 0.92 HDAC3 (0.37) HDAC3HDAC1HDAC2NCOR2MAPT
SCHEMBL7704902 0.92 RIPK1 (0.37) HDAC3HDAC1HDAC2NCOR2
SCHEMBL7711458 0.91 HDAC3 (0.33) HDAC3HDAC1HDAC2NCOR2CYP2C19
SCHEMBL7704910 0.91 HDAC1 (0.45) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL7708018 0.91 ERCC1 (0.33) HDAC3HDAC1HDAC2NCOR2MAPT
SCHEMBL7708353 0.90 GRM2 (0.37) HDAC3HDAC1HDAC2NCOR2NR1D1
SCHEMBL7711328 0.89 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2MAPT
SCHEMBL7704946 0.89 ALDH1A1 (0.38) HDAC3HDAC1HDAC2NCOR2NR1D1
SCHEMBL7704988 0.89 HDAC3 (0.36) HDAC3HDAC1HDAC2NCOR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed